Wedbush Has Positive Forecast for TCRX FY2028 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Wedbush raised their FY2028 earnings per share (EPS) estimates for TScan Therapeutics in a report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $0.46 per share for the year, up from their previous estimate of $0.40. Wedbush currently has a "Outperform" rating and a $10.00 price target on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.17) per share.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC restated a "buy" rating and issued a $11.00 target price on shares of TScan Therapeutics in a research note on Tuesday. HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $12.00.

TScan Therapeutics Stock Down 8.2 %

TCRX traded down $0.43 during trading on Thursday, hitting $4.82. The company had a trading volume of 166,315 shares, compared to its average volume of 246,925. The company has a market cap of $255.32 million, a PE ratio of -4.78 and a beta of 0.79. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.77 and a quick ratio of 7.77. TScan Therapeutics has a 1-year low of $3.73 and a 1-year high of $9.69. The business has a 50-day moving average of $5.34 and a 200-day moving average of $6.52.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02. The company had revenue of $0.54 million during the quarter, compared to analysts' expectations of $1.55 million. TScan Therapeutics had a negative return on equity of 63.11% and a negative net margin of 1,188.88%.

Insider Activity

In other TScan Therapeutics news, insider Zoran Zdraveski sold 164,686 shares of the firm's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now directly owns 4,716 shares in the company, valued at approximately $27,258.48. This trade represents a 97.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Barbara Klencke purchased 5,000 shares of the stock in a transaction dated Monday, September 23rd. The shares were purchased at an average price of $5.29 per share, with a total value of $26,450.00. Following the transaction, the director now directly owns 45,000 shares of the company's stock, valued at approximately $238,050. The trade was a 12.50 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders acquired 15,000 shares of company stock valued at $82,550. Company insiders own 2.76% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TCRX. Dimensional Fund Advisors LP acquired a new position in shares of TScan Therapeutics during the second quarter worth approximately $70,000. The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics during the 2nd quarter worth $90,000. SG Americas Securities LLC bought a new position in shares of TScan Therapeutics in the third quarter worth $78,000. Cornercap Investment Counsel Inc. acquired a new position in shares of TScan Therapeutics during the second quarter valued at $134,000. Finally, MetLife Investment Management LLC raised its stake in shares of TScan Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company's stock valued at $116,000 after purchasing an additional 13,164 shares in the last quarter. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.